Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus-associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant Tcell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display preferential in vivo expansion. Both viral and nonviral tumor antigen-specific T cells resided predominantly in the programmed cell death 1 (PD-1)-expressing T cell compartment, which suggests that PD-1 blockade may unleash diverse antitumor T cell reactivities. These findings suggest a new paradigm of targeting nonviral antigens in immunotherapy of virally associated cancers.
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Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus-associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant Tcell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display preferential in vivo expansion. Both viral and nonviral tumor antigen-specific T cells resided predominantly in the programmed cell death 1 (PD-1)-expressing T cell compartment, which suggests that PD-1 blockade may unleash diverse antitumor T cell reactivities. These findings suggest a new paradigm of targeting nonviral antigens in immunotherapy of virally associated cancers.
I mmunotherapy can induce the regression of certain virally associated epithelial malignancies such as human papillomavirus (HPV)-induced cervical (1), head and neck (2) , and anal (3) cancers. The viral oncoproteins expressed by HPV + tumors are potential candidate tumor regression antigens, as they are immunologically foreign and are constitutively expressed by cancer cells (4) . However, evidence supporting their role in immunotherapy-mediated tumor regression is limited. Efforts to induce cancer regression by targeting HPV oncoproteins with antigen-specific immunotherapy, such as therapeutic vaccines, have not been effective (5, 6) . Adding chemotherapy to therapeutic vaccines reduces myeloid-derived suppressor cells and augments immunogenicity, but whether this improves the efficacy of vaccine treatments remains unknown (7) . It is also intriguing that response rates to programmed cell death 1 (PD-1) immune checkpoint blockade appear to be similar in patients with virus-positive and -negative head and neck carcinomas (2) . T cells targeting the protein products of somatic mutations (mutated neoantigens) (8-11) and epigenetically dysregulated genes (cancer germline antigens) (12, 13) have been implicated in immunotherapy-induced regression of certain nonviral cancers. Thus, one explanation unifying these observations may be that nonviral tumor antigens are targeted in regression of HPV + cancers. To explore this hypothesis, we performed a global landscape analysis of the viral and nonviral antigens targeted by T cells in patients successfully treated with immunotherapy for a virally associated epithelial cancer.
We studied two patients with HPV + metastatic cervical carcinoma who experienced complete cancer regression that is ongoing now at 54 months (patient 3775 with HPV16 + squamous cell carcinoma) and at 46 months (patient 3853 with HPV18 + adenocarcinoma) after adoptive transfer of tumor-infiltrating lymphocytes (TILs) (1) . The infused T cells, hereafter referred to as TIL-3775 and TIL-3853, were expanded from TIL cultures selected for HPV-E6 and/or HPV-E7 oncoprotein reactivity (1) . However, these cultures also contained T cells with uncharacterized antigen specificities. To fully define the antigens targeted by the therapeutic T cells, we combined next-generation sequencing with functional immunological assays and examined T cell reactivity against HPV-encoded antigens, mutated neoantigens, and cancer germline antigens ( fig. S1 ) (14) .
We first investigated whether the infused TILs displayed T cell reactivity against HPV-encoded proteins (14) . Consistent with prior results, T cells specific for the HPV-E6 and/or HPV-E7 antigens were detected in both patients (Fig. 1 , A and B) (1) . Reactivity against other HPV proteins was not found (Fig. 1, A and B, and table S1). In TIL-3775, the response against HPV-E6 was CD8
+ T cell-mediated, whereas CD4 + and CD8 + T cells recognized HPV-E7 (Fig. 1C) . The T cell response against HPV-E7 in TIL-3853 was CD4 + T cell-mediated (Fig. 1D ). We next used the tandem minigene (TMG) approach (15) to investigate whether the infused TILs displayed reactivity against mutated neoantigens (14) . TIL-3775 was screened for reactivity against 19 TMG constructs that together encoded 222 identified somatic mutations (14) . We detected specific CD8 + T cell-mediated reactivity to TMG-1, TMG-5, and TMG-18 ( Fig. 1,  E and F) . Subsequent screening of individual mutant peptides encoded by the recognized TMGs (table S2) revealed reactivity to neoepitopes derived from SETDB1 (SET domain bifurcated 1), METTL17 (methyltransferase-like 17), and ALDH1A1 (aldehyde dehydrogenase 1 family member A1) (Fig.  1G and fig. S2A ). T cells preferentially recognized the mutant peptides ( Fig. 1H and fig. S2 , B and C). TIL-3853 was also screened for T cell reactivity against 72 identified somatic mutations (14) ; however, no responses were detected.
Next, the infused TILs were examined for reactivity against cancer germline antigens (14). TIL-3775 did not demonstrate reactivity against any of the seven antigens tested (table S1) . TIL-3853 demonstrated CD8 + T cell reactivity against a single cancer germline antigen, KK-LC-1 (KitaKyushu lung cancer antigen 1) (Fig. 1, I and J, and table S1). Thus, in addition to T cells targeting the HPV oncoproteins, T cells with reactivity against mutated neoantigens or a cancer germline antigen contributed to the pool of infused T cells in each of the effective treatments.
To characterize the polyclonality of T cell responses targeting the tumor antigens, we identified antigen-specific T cell receptor (TCR) sequences from the infused TILs ( fig. S3 ) using single-cell reverse transcription polymerase chain reaction (14, 16) and/or pairSEQ [a statistical model for pairing TCR a-chain (TCRA) and TCR b-chain (TCRB) sequences; Adaptive Biotechnologies] (14, 17) . Paired TCRA and TCRB sequences obtained using these methods (fig. S3 and table S3) were then used to reconstruct TCRs (14, 16) . Subsequently, these reconstructed TCRs were cloned into retroviral vectors and were used to genetically engineer autologous peripheral blood T cells (14, 16) . For patient 3775, one CD8 + T cellderived TCR demonstrated specific HPV-E6 recognition; an additional two CD8 + and two CD4 + T cell-derived TCRs displayed HPV-E7 reactivity ( Fig. 2A) . Five, one, and two CD8 + T cell-derived TCRs demonstrated recognition of mutated SETDB1 E>D , METTL17 E>K , and ALDH1A1 N>I , respectively ( Fig.  2A) . For patient 3853, one CD4 + T cell-derived TCR conferred specific HPV-E7 reactivity, and one CD8 + T cell-derived TCR recognized KK-LC-1 (Fig. 2B) . Thus, T cells targeting viral and nonviral tumor antigens infused into the patients were monoclonal or oligoclonal.
We next used TCRB deep sequencing to determine the relative frequencies of the identified tumor antigen-specific TCR clonotypes in the infused TILs. In TIL-3775, the five HPV-specific and eight mutated neoantigen-specific TCR clonotypes were found at variable frequencies (ranges, 0.7 to 4.7% and 0.1 to 6.9%) and ranks (ranges, 6 to 33 and 1 to 65) (Fig. 2C) . The cumulative frequency of mutated neoantigen-specific TCR clonotypes accounted for 35% of TIL-3775, whereas the HPV-specific TCR clonotypes represented 14% (Fig.  2C ). In TIL-3853, the KK-LC-1-specific TCR clonotype was the most frequent at 67%, and the HPV-E7-specific TCR clonotype was the second most common at 14% (Fig. 2D) . Thus, both patients received TILs that contained a low frequency of HPV-targeted T cells relative to the frequency of nonviral tumor antigen-targeted T cells.
To directly compare the functional avidity of TCRs targeting the viral and nonviral tumor antigens identified in the infused TILs, we cocultured TCR-transduced T cells with antigenpresenting cells pulsed with titrated concentrations of cognate T cell epitopes ( fig. S4 and table S4). For patient 3775, the HPV-specific and mutated neoantigen-specific TCRs exhibited functional avidities spanning 10 -1 to 10 -4 mg/ml and 10 -3 to 10 -5 mg/ml of cognate peptide, respectively ( Fig. 2E ). For patient 3853, the HPV-specific and KK-LC-1-specific TCRs displayed recognition of as low as 10 -2 mg/ml and 10 -3 mg/ml of cognate peptide, respectively ( Fig.   2F ). Thus, both viral and nonviral tumor antigentargeting TCRs displayed a range of functional avidities.
We next evaluated the function and persistence of adoptively transferred tumor antigen-specific T cells in the circulation. Posttreatment peripheral blood T cells from both patients displayed specific reactivity against all identified tumor antigens, whereas minimal to no reactivity was detected before treatment (Fig. 3, A and B) . In patient 3775, tumor antigen-specific TCR clonotypes represented 27 to 29% of T cells during tumor regression and 2% during remission, whereas they accounted for 0.06% of pretreatment T cells (Fig. 3C) . The proportion of HPV-specific T cells relative to mutated neoantigen-specific T cells was similar during tumor regression and remission (Fig. 3C) . In patient 3853, tumor antigen-specific TCR clonotypes accounted for 12% of T cells during tumor regression and 3% during remission, whereas they represented 0.003% of pretreatment T cells (Fig. 3D) . The frequency of the KK-LC-1-specific TCR clonotype exceeded that of the HPV-specific TCR clonotype by a factor of at least 10 across all time points measured (Fig. 3D) . Taken together, infused tumor antigen-reactive T cells in both patients remained functional and persisted at (14) .
Tcell reactivity was measured at 20 to 24 hours in coculture assays.The TCR transduction efficiencies were >40%. P/I stimulation was used as a positive control in all coculture assays (not shown). elevated levels in the circulation during tumor regression and remission. Cell surface expression of PD-1 on circulating CD8 + T cells functions as a biomarker to identify tumor antigen-specific T cells in metastatic melanoma patients (18) , but whether it identifies these T cells in patients with epithelial cancers is unknown. In both patients we studied, a minor population representing ≤10% of CD4 + and CD8 + T cells coexpressed PD-1 in pretreatment peripheral blood (Fig. 4A) . Using flow cytometric sorting followed by TCRB deep sequencing, we subsequently identified TCR clonotypes within the circulating PD-1 + and PD-1 -T cell populations. Of 13 tumor antigen-specific TCR clonotypes, 12 (including those associated with HPV and mutated neoantigen reactivities) were uniquely detected in the PD-1 + T cell population, but not the PD-1 -T cell population, of patient 3775 (Fig. 4B) . For patient 3853, both the HPVspecific and KK-LC-1-specific TCR clonotypes were enriched in the PD-1 + T cell population relative to the PD-1 -T cell population (Fig. 4C ).
These findings show that PD-1 expression can identify both viral and nonviral tumor antigenspecific T cells in peripheral blood of cervical cancer patients. This study reveals the targeting of both viral and nonviral tumor antigens by adoptively transferred TILs in complete regression of metastatic HPV + cervical cancer in two patients. The immunodominant T cell reactivity in infused TILs was directed against mutated neoantigens in one patient (35% of TILs) and the cancer germline antigen KK-LC-1 in another patient (67% of TILs). HPV antigen-targeted T cells represented a subdominant population of administered tumor-specific T cells in both cases (14% of TILs). Given the variety of infused tumor antigen-specific T cells, as well as T cells with undefined specificity, the T cell component(s) responsible for tumor eradication cannot be precisely determined. The relatively high frequency of infused and persisting viral and nonviral tumor antigenspecific T cells suggests that they might have contributed to the cancer regressions. It would have been valuable to test the tumor antigenspecific T cells for autologous tumor recognition. Unfortunately, tumor cell lines from these patients could not be generated. Given this limitation, the immunogenomic approach used in this study was a necessary surrogate to assess T cells for reactivity against patient-specific tumor antigens. Finally, the finding that both viral and nonviral tumor antigen-targeting T cells resided preferentially in the circulating PD-1 + T cell compartment suggests that anti-PD-1 blockade therapy may act through targeting of a variety of tumor antigen-specific T cells in HPV + cancers. These results have important implications for the development and immune monitoring of immunotherapies for cervical cancer and possibly other virally induced cancers.
The immunogenicity of somatic mutations and of the cancer germline antigen KK-LC-1 in cervical cancer revealed in this study might be exploited for therapeutic benefit. Inactivation of the tumor suppressor proteins p53 and pRb (by the highrisk HPV-E6 and HPV-E7 oncoproteins, respectively) impedes DNA damage repair in HPVtransformed cells (19, 20) . Consequently, these cells can accumulate genomic alternations at an accelerated pace, including a variable number of somatic mutations (21, 22 ) that might be expressed as neoantigens. The immunogenic mutations identified in patient 3775 were unique (23) . As such, targeting this class of tumor antigens requires patient-specific personalized therapy (24) . By contrast, TILs from patient 3853 targeted KK-LC-1, a shared cancer germline antigen expressed in 40% (12/30) of metastatic cervical cancers we tested. T cell reactivity against KK-LC-1 was detected in TILs from 2/8 additional KK-LC-1 + cervical cancers, which suggests that it is naturally immunogenic ( fig. S5 ). Furthermore, KK-LC-1 is expressed in gastric cancers (81%) (25), triple-negative breast cancers (53%) (26) , and non-small cell lung cancers (40%) (27) . KK-LC-1 is not expressed in normal nongermline tissues (26) , which suggests that it may be safely targeted by T cells. The identified KK-LC-1-specific human leukocyte antigen (HLA)-A*01:01-restricted TCR ( fig. S4 , B and H) conferred recognition of peptide-pulsed and antigen-positive target cells, as evidenced by interferon-g (IFN-g) production ( fig. S6, A to C) . In addition, KK-LC-1-specific TCR-transduced T cells as well as TIL-3853 produced tumor necrosis factor-a, mobilized CD107a ( fig. S6D ), and exerted cytolytic activity ( fig. S6E ) against cancer cell lines in an antigenand HLA-dependent manner. Thus, these data demonstrate the potential for a novel treatment paradigm of targeting nonviral tumor antigens in virally associated cancers. HPV + cancers harbor the E6 and E7 oncoproteins, historically the primary targets for antigenspecific immunotherapies in these malignancies (4) . Despite their foreign nature, only 43% (23/54) of cervical cancer TILs were shown to possess oncoprotein reactivity (28, 29) . We found that the frequency of oncoprotein-reactive T cells infiltrating the metastatic tumors in our patients was similar to or less than that of mutated neoantigen-specific or cancer germline antigenspecific T cells (table S5) 
